Comparative Pharmacology
Head-to-head clinical analysis: BUTABARBITAL SODIUM versus NEMBUTAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTABARBITAL SODIUM versus NEMBUTAL SODIUM.
BUTABARBITAL SODIUM vs NEMBUTAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.
Barbiturate that enhances GABA-A receptor activity, prolonging chloride channel opening and increasing neuronal inhibition. Depresses the reticular activating system at higher doses.
Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.
30 mg IV or IM every 6 to 8 hours as needed for sedation; 65 to 100 mg IV or IM for hypnosis; 200 to 500 mg IV or IM for anticonvulsant effect in status epilepticus. Maximum single dose 500 mg.
None Documented
None Documented
Terminal elimination half-life: 30-50 hours; accumulates with repeated dosing, prolonged in hepatic impairment
Terminal elimination half-life: 15-40 hours in adults; clinically relevant for accumulation with repeated dosing, especially in hepatic impairment.
Renal: 50-70% as metabolites (hydroxylated and conjugated forms), 5-10% unchanged; fecal: minor (<5%)
Renal: ~25% unchanged; hepatic metabolism to inactive metabolites; ~50% excreted as metabolites in urine; biliary/fecal: minor.
Category C
Category C
Barbiturate
Barbiturate